Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Promis Neurosciences Inc. currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners. This indicates that each pending case is being reviewed by a different individual. However, the 1 distinct art unit involved shows that both actions are being handled within the same administrative section.
WANG, CHANG YU is the busiest examiner for this portfolio. This examiner is responsible for 1 pending office action. Since there are 2 pending actions and 2 examiners, the workload is split perfectly between them. The concentration of both cases in a single art unit suggests that the underlying technology is administratively grouped together despite the use of different examiners.
For a practitioner, this distribution requires managing two separate examiner relationships within a single art unit environment. The feedback from WANG, CHANG YU may be influenced by the same art unit policies that affect the other pending action. The practitioner should look for consistency in prior art citations across the 2 pending office actions while tailoring arguments to the specific preferences of each examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WANG, CHANG YU | 1 | 33.4% | +53.7% |
| BALLARD, KIMBERLY | 1 | 53.6% | +49.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17921277 | SINGLE CHAIN ANTIBODIES AND INTRABODIES TO MISFOLDED TDP-43 AND METHODS OF USE | WANG, CHANG YU | — |
| 17916302 | ANTIBODIES TO MISFOLDED AMYLOID BETA | BALLARD, KIMBERLY | — |
| Art Unit | Apps |
|---|---|
| 1675 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17921277 | SINGLE CHAIN ANTIBODIES AND INTRABODIES TO MISFOLDED TDP-43 AND METHODS OF USE | WANG, CHANG YU | 1675 | §112 | Non-Final OA | — | Pending | Oct 25, 2022 |
| 17916302 | ANTIBODIES TO MISFOLDED AMYLOID BETA | BALLARD, KIMBERLY | 1675 | §112 | Non-Final OA | — | Pending | Sep 30, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPromis Neurosciences Inc. has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Chang Yu Wang has the most, with 1 of Promis Neurosciences Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
